FDA Clears Triton Robotic Endoscopy System for Colon Procedures

The FDA has granted 510(k) clearance to the Triton 1 Robotic Endoscopy System for diagnostic and therapeutic procedures throughout the colon, according to a news release from the developer, Neptune Medical.¹ The system is designed to bring robotic precision, stability, and control to colonoscopy and related procedures, including endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD).

What clinical data supported the FDA clearance?

The clearance follows results from the first-in-human, interventional CARE 1 study (NCT06935734) of 50 adults who underwent screening, surveillance, or diagnostic colonoscopy with the Triton system at a single center in Poland and were followed for 14 days after the procedure.² The study, presented earlier this year in a late-breaking oral presentation at Digestive Disease Week 2026, met both of its primary end points, with no adverse events and 100% cecal intubation. The system also demonstrated an adenoma detection rate of 54.2%, as well as a polyp detection rate of 67.5% and 100% polypectomy success. Investigators reported no patient repositioning, abdominal pressure, or conversion to manual colonoscopy. Using the NASA Task Load Index, the system was also associated with a 67% lower average physical and mental burden for endoscopists compared with manual colonoscopy.

“Bringing robotics to lower [gastrointestinal] procedures is an exciting prospect for us,” stated Jason B. Samarasena, MD, chief of the division of gastroenterology and hepatology at the University of California, Irvine, and investigator on the CARE 1 trial, in the press release.¹ “Triton showed us the possibility of 1 system that can screen and treat anywhere in the colon, efficiently, thoroughly, and with minimal burden. I look forward to participating in additional clinical research of the system that will support its progress along the path to commercialization.”

What is the Triton 1 System designed to do?

The Triton 1 System is intended to elevate any endoscopist's capabilities for screening, surveillance, and diagnostic colonoscopies, as well as more complex procedures throughout the colon such as EMR and ESD. The system is built on the Dynamic Rigidization platform technology, which is designed to enable more consistent scope control than manual endoscopes.

“Triton has the potential to fundamentally transform colonoscopy, creating a better experience for both physicians and their patients. Achieving regulatory clearance in the US brings us one step closer to that reality,” added Alex Tilson, founder and chief executive officer of Neptune Medical, in the press release.¹ “We are using this generation of the Triton system to build on the evidence from our recent trial and to learn from endoscopists how robotics should integrate into their workflow—insights that will directly shape our next-generation platform.”

How does the Triton system work?

Triton is built on Neptune Medical's Dynamic Rigidization technology, the same underlying mechanism that the Pathfinder Endoscope Overtube, developed by the same company, utilizes. According to the 510(k) filing for pathfinder, the technology consists of a flexible overtube connected via a stopcock to a vacuum line; venting the enclosed vacuumable volume to the atmosphere keeps the overtube flexible, while connecting it to a vacuum source causes it to hold its shape and transition to a rigid state.³ This allows an endoscope to advance or withdraw through the tube with minimal disturbance to the surrounding anatomy, which helps limit the looping that commonly destabilizes manual scope navigation through the colon. Triton extends this same rigidizing platform into a robotic system, pairing it with robotic control of scope navigation to give endoscopists a more stable, hands-off approach to reaching and maneuvering throughout the entire colon.

Why does robotic assistance matter for colorectal cancer screening?

Colorectal cancer is the second leading cause of cancer death in the US and is increasingly affecting adults under age 50. Colonoscopy remains the gold standard for colorectal cancer diagnosis, prevention, and treatment, as it is the only procedure that allows for both detection and removal of precancerous lesions in a single session. However, conventional endoscopes have design limitations that can make them difficult to control even for gastroenterologists with years of specialized training; scope instability can lead to incomplete visualization, missed adenomas, and an increased risk of cancer development, while manual endoscopy can also create significant physical stress for the clinician.

References

1. Neptune Medical receives FDA clearance for Triton robotic endoscopy system. News release. Neptune Medical. September 16, 2026. Accessed September 17, 2026. https://tinyurl.com/bd9bh92j
2. 50-patient first-in-human study of Triton robotic endoscopy system from Neptune Medical demonstrates no adverse events and 100% cecal intubation in colonoscopy. News release. Neptune Medical. May 5, 2026. Accessed September 17, 2026. https://tinyurl.com/7anf4ums
3. 510(k) Summary: Pathfinder Endoscope Overtube (K191415). Neptune Medical, Inc. FDA. August 30, 2019. Accessed September 17, 2026. https://tinyurl.com/bdctvmby